(ADMA)
NGM – Real Time Price. Currency in USD
9.25
+0.96 (11.58%)
At close: Mar 27, 2026, 4:00 PM EDT
9.40
+0.15 (1.62%)
After-hours: Mar 27, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
9.25
+0.96 (11.58%)
At close: Mar 27, 2026, 4:00 PM EDT
9.40
+0.15 (1.62%)
After-hours: Mar 27, 2026, 7:59 PM EDT
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
| Name | Position |
|---|---|
| Dr. Jerrold B. Grossman D.P.S., Ph.D. | Co-Founder & Vice Chairman of the Board |
| Mr. Adam S. Grossman | Co-Founder, President, CEO & Director |
| Mr. Brad Tade | Consultant |
| Mr. John Hafl | Executive Director of Sales |
| Mr. Michael Goldstein | General Counsel |
| Mr. P. Terence Kohler | CFO & Treasurer |
| Mr. Skyler Bloom | Senior Director of Business Development & Corporate Strategy |
| Ms. Kaitlin Kestenberg | COO & Senior VP of Compliance |
| Date | Type | Document |
|---|---|---|
| 2026-03-02 | 8-K | ef20066774_8k.htm |
| 2026-01-12 | 8-K | ef20062685_8k.htm |
| 2025-11-05 | 10-Q | ef20054948_10q.htm |
| 2025-08-06 | 8-K | ef20053140_8k.htm |
| 2025-06-04 | 8-K | ef20050181_8k.htm |
| 2025-05-07 | 8-K | ef20048524_8k.htm |
| 2025-04-28 | 8-K | ef20048038_8k.htm |
| 2025-04-15 | DEF 14A | ny20042262x771_def14a.htm |
| 2025-03-18 | 10-K | ef20038923_10k.htm |
| 2025-03-03 | 8-K | ef20044777_8k.htm |